Prosecution Insights
Last updated: July 17, 2026
Application No. 18/458,239

METHOD FOR PRODUCING PENTAFLUOROSULFANYL GROUP-CONTAINING ARYL COMPOUND

Final Rejection §103§112
Filed
Aug 30, 2023
Priority
Mar 02, 2021 — JP 2021-032818 +1 more
Examiner
TRAN, ERIC
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The University of Tokyo
OA Round
2 (Final)
70%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
73 granted / 104 resolved
+10.2% vs TC avg
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
40 currently pending
Career history
138
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
44.7%
+4.7% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 104 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Per Applicant’s amendment to the claims, submitted on 05/01/2026, claims 1-5 are amended, and claims 6-7 are canceled. Currently, claims 1-5 are pending in the instant application. Claim Rejections - 35 USC § 112 First Paragraph - Withdrawn Rejections of claims 1-5: In light of Applicant’s amendment to the claims, the rejections are hereby withdrawn. The claims have been amended to specify the use of silver (II) fluoride and a tetraalkylammonium halide. Claim Rejections - 35 USC § 103 - Maintained Claim(s) 1-5 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ou (previously referenced) in view of Williams (previously referenced). Response to Remarks: Applicant’s arguments are not persuasive, the rejections are hereby maintained. Firstly, Applicant contends that the substitution of the XeF2 reagent for the AgF2 reagent taught by Williams would constitute a change in the principle operation of the prior art. However, the principle operation of the teachings of Ou have not been rendered inoperable. Ou teaches a method of fluorinating aryl sulfur compounds by oxidative fluorination in order to arrive at an aryl sulfur pentafluoro compound (Eq. (2)): PNG media_image1.png 46 297 media_image1.png Greyscale In the case of Ou, XeF2 is used as an oxidizing agent and fluorine donor to form the pentafluoro species, while Et4NCl appears to be used in order to enable a higher oxidation state for the sulfur species (i.e., sulfur (VI)), providing an environment more favorable for the formation of sulfur pentafluoro species. In Williams, AgF2 is used in the same manner as a fluoride donor for the formation of sulfur pentafluoro moieties (specification page 4)1. Even if, in one aspect, the study of Ou was conducted to demonstrate the utility of XeF2, it would have been readily recognizable to a person of ordinary skill in the art that XeF2 and AgF2 would have a degree of predictable analogous function in the context of oxidative fluorination. While Applicant may not be explicitly incorrect with regards to the intent of the study of Ou, the prior art is valuable for what it teaches as a whole, rather than just its end goal or intended purpose. Accordingly, a person of ordinary skill in the art would have a reasonable expectation that the substitution of XeF2 for AgF2 in the method of Ou would successfully be able to synthesize the target sulfur pentafluoro compounds. Secondly, Applicant contends non-obviousness on the grounds that Williams teaches the use of solvents different from the “aprotic polar solvent” now recited in claim 1. While Applicant is not explicitly incorrect regarding the lone teachings of Williams regarding the solvent, it still remains that the rejection exists over the combination of the teachings of both Ou and Williams. Williams may teach the use of certain high boiling point hydrocarbon solvents, but Ou teaches the use of CD2Cl2 as a solvent. For example Ou provides the following exemplary preparation (page 282): “To PhSSPh (17 mg, 0.078 mmol) in CD2Cl2 (0.3 mL) in a ptfe-lined NMR tube was added Et4NCl (2 mg, 0.012 mmol) at 258C. Solid XeF2 (82 mg, 0.48 mmol) was then added slowly to the reaction mixture and the colourless solution turned yellow, with gas evolution. After 30 min, another batch of Et4NCl (6 mg, 0.036 mmol) was added. Gas evolved vigorously and the solution turned deep yellow and back to colourless, to give PhSF5 (25%), identified by 19F NMR [3], along with some trans-PhSF4Cl.” CD2Cl2 is considered as being an aprotic polar solvent, being a deuterated analog of dichloromethane. As iterated previously, the combined teachings of Ou and Williams provide a reasonable obvious substitution of XeF2 for AgF2, and further appear to teach each of the aspects of the instant claims. Accordingly, the rejections of claims 1-5 are hereby maintained. The reiterated rejection will be provided below for the purpose of clarity and reference. Reiterated Rejections: Claim 1 recites a method for producing a pentafluorosulfanyl group-containing aryl compound represented by formula (1): PNG media_image2.png 44 172 media_image2.png Greyscale From a thioaryl compound of formula (2): PNG media_image3.png 41 174 media_image3.png Greyscale By oxidative fluorination reaction using a divalent or higher valent metal fluoride and an organic salt including a quaternary ammonium cation or a quaternary phosphonium ion. Ou teaches the synthesis of aryl sulfur pentafluorides. More specifically, the formation through oxidative fluorination of phenyl sulfur pentafluoride (PhSF5) by combining phenyl disulfide, xenon disulfide, and NEt4Cl, wherein the overall reaction is provide below (page 279, (2)): PNG media_image4.png 72 512 media_image4.png Greyscale The phenyl disulfide used by Ou is a compound of formula (2) wherein A1 is phenyl (i.e., unsubstituted aryl) and G1 is S-S-R1, wherein R1 is unsubstituted aryl. The resulting product of PhSF5 is a compound of formula (1) wherein A1 is phenyl. Furthermore, Ou uses the quaternary ammonium salt NEt4Cl. In an exemplary synthesis, PhSF5 was produced at a 25% yield (page 282)2. Ou does not explicitly teach the use of a divalent or higher valent metal fluoride. However, the use of such a metal fluoride would be obvious because Ou indicates that it is known in the art that aryl sulfide pentafluorides can be formed using AgF2, and Williams teaches the use of silver difluoride (AgF2) to convert aryl disulfides to aryl sulfur pentafluorides at greater yield. As indicated above, Ou does not explicitly teach the use of AgF2, however they do make mention that AgF2 can be used to form aryl sulfur pentafluorides (page 279)3. Similarly to Ou, Williams teaches a method of synthesizing aryl sulfur pentafluorides from aryl disulfides. However, the teachings of Williams differ from the teachings of Ou in that Williams combines aryl disulfides with AgF2 to form the final aryl sulfur pentafluoride. The general method of Williams is provided in the diagram below (Page 12, Scheme 1): PNG media_image5.png 412 597 media_image5.png Greyscale Williams further provides an exemplary synthesis wherein 4-nitrophenyldisulfide (50 g) is combined with AgF2 (400 g) and heated to 122-124C for 6 hours in order to form the final nitrophenyl pentasulfide (page 7)4. Williams’ synthesis provided product in 99% purity and a yield of 78% (page 7)5. As the method of Williams appears to provide a higher yield of final product, a person or ordinary skill in the art would be motivated to use AgF2 as a fluorination agent rather than the XeF2 of Ou. It would have been prima facie obvious at the time of invention for a person of ordinary skill in the art to combine the teachings of Ou and Williams, and substitute the use of XeF2 of Ou, for the AgF2 used by Williams, because there would be a reasonable expectation that the yield of the final aryl sulfur pentafluoride product would be greater. Claim 2 further limits the method of claim 1 wherein A1 is: PNG media_image6.png 437 606 media_image6.png Greyscale Ou teaches PhSF5 which is a compound of formula (1) wherein A1 is unsubstituted aryl. Claim 3 further limits the method of claim 1 wherein the oxidative fluorination reaction is carried out at -40 to 130C. Ou teaches reaction at 25C. Claim 4 further limits the method of claim 1 wherein a metal produced after the oxidative fluorination is recovered. Williams teaches that AgF2 is consumed in reaction to form AgF, which can be collected and re-fluorinated into AgF2 for repeated use (pages 4-5)6. Claim 5 further limits the method of claim 4 wherein the recovered metal is fluorinated to regenerate a divalent or higher valent metal fluoride, and the obtained divalent or higher valent metal fluoride is used again in the oxidative fluorination reaction. As iterated in the claim 4 rejection, Williams teaches that AgF2 is consumed in reaction to form AgF, which can be collected and re-fluorinated into AgF2 for repeated use. Conclusion Claims 1-5 are rejected. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIC TRAN whose telephone number is (571)272-7854. The examiner can normally be reached Mon-Fri 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached at (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERIC TRAN/Examiner, Art Unit 1629 1 “Thus whilst the excess silver difluoride used in the process of the present invention .represents an expensive capital outlay, the silver may be used effectively as a carrier for the fluorine used in the formation of the sulphurpentafluoride moiety and may be re-cycled repeatedly without serious loss.” 2 “To PhSSPh (17 mg, 0.078 mmol) in CD2Cl2 (0.3 mL) in a ptfe-lined NMR tube was added Et4NCl (2 mg, 0.012 mmol) at 258C. Solid XeF2 (82 mg, 0.48 mmol) was then added slowly to the reaction mixture and the colourless solution turned yellow, with gas evolution. After 30 min, another batch of Et4NCl (6 mg, 0.036 mmol) was added. Gas evolved vigorously and the solution turned deep yellow and back to colourless, to give PhSF5 (25%), identified by 19F NMR” 3 “Arylsulfur pentafluorides have been made previously by the reaction of AgF2 with aryl disulfides or arylsulfur trifluorides” 4 “4-Nitrophenyldisulphide (50g) was charged to the reaction vessel and agitation was commenced. Silver difluoride (400g) was added in one portion to the stirred mixture at ambient temperature from a solid addition funnel designed to maintain an inert atmosphere over the contents during the charging procedure. Last traces of silver difluoride were rinsed into the reactor with (50 mls) of octane. The temperature of the reactor and contents was raised over 2 hours to 122 - 124°C and held at this temperature for 6.5 hours.” 5 “The chloroform eluents were evaporated to give 74 grams of product whose purity was estimated as 99% by HPLC whilst GC analysis indicated 16% octane/hydrocarbon content. The yield was thus 78% (based on disulphide charged and GC analysis of purity).” 6 “Silver difluoride consumed during the reaction is converted to silver fluoride which is also insoluble under the reaction conditions. Silver fluoride and any unreacted silver difluoride remaining after the reaction is complete are thus readily recovered by filtration, optionally with washing using a suitable solvent. Silver difluoride is readily re-formed by the treatment of silver fluoride with a fluorinating agent such as gaseous fluorine. Thus whilst the excess silver difluoride used in the process of the present invention represents an expensive capital outlay, the silver may be used effectively as a carrier for the fluorine used in the formation of the sulphurpentafluoride moiety and may be re-cycled repeatedly without serious loss.”
Read full office action

Prosecution Timeline

Aug 30, 2023
Application Filed
Feb 06, 2026
Non-Final Rejection mailed — §103, §112
May 01, 2026
Response Filed
Jun 29, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12643881
BICYCLIC AMINE CDK12 INHIBITORS
3y 6m to grant Granted Jun 02, 2026
Patent 12636288
METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION
6y 2m to grant Granted May 26, 2026
Patent 12637440
NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF
3y 11m to grant Granted May 26, 2026
Patent 12622895
ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES
5y 1m to grant Granted May 12, 2026
Patent 12617783
HETEROCYCLIC GLP-1R AGONISTS
1y 1m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
70%
Grant Probability
94%
With Interview (+23.6%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 104 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month